Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOLEDDO semaglutide in double diabetes
2024-514906-30-00Phase 3Authorised
- Sponsor
- Centre Hospitalier Universitaire Dijon Bourgogne
- Start
- Jul 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of semaglutide in diabetes mellitus type 1 (T1D) and obesity (2 arms), sponsored by Centre Hospitalier Universitaire Dijon Bourgogne. Primary endpoint: Percentage of time spent in glycemic target range. Planned start Jul 2022; status: authorised.
02
Drugs
03
Conditions
diabetes mellitus type 1 (T1D)obesity
Beyond the preview
Go deeper on 2024-514906-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514906-30-00.